Association between early childhood oral health impact scale (ECOHIS) scores and pediatric dental surgery wait timesResearch Article Published on 2020-10-172022-10-28 Journal: BMC Oral Health [Category] Coronavirus, Fulltext, MERS, SARS, [키워드] 95% confidence interval access age Analysis approved association Bivariate analyses board Care Cary childhood children CIs correlated correlation correlation coefficient COVID-19 database determine Early childhood caries ECOHIS Ethics female general anesthesia Health help Hypothesis Impact majority measure Observed oral Oral health-related quality of life, wait times P -value participated pediatric Preschool child Quality of life questionnaire receive recruited registry reported Result scale significantly statistically statistically significant surgical tooth Treatment university Winnipeg [DOI] 10.1186/s12903-020-01263-8 PMC 바로가기 [Article Type] Research Article
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial이중 맹검, 무작위, 위약 대조 임상 3상 임상 시험을 통해 의료 전문가를 Sinovac에서 제조한 흡착된 COVID-19(불활성화) 백신으로 치료하는 효과와 안전성을 평가합니다. – PROFISCOV: 무작위 대조를 위한 연구 프로토콜의 구조화된 요약 재판Letter Published on 2020-10-152022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 95% confidence interval Active surveillance adjuvant Administered administration Adults adverse event adverse events Adverse reaction Adverse reactions age Aluminium aluminium hydroxide Analysis attack rate Beijing blind Blinding Brazil Breastfeeding calculated Care causal relationship China clinical clinical care clinically Committee completion confirmed case Consent consent form Contact contact with Control COVID-19 criterion database defined Diagnosis direct contact disease dissemination dose double-blind double-blind study Efficacy Efficacy and safety elderly element Endpoint evaluate exclusion criteria expected experimental intervention FDA form Frequency genders Health Health Organization hydroxide immunogenicity inactivated Inactivated Vaccines incidence include Inclusion information Informed intramuscular dose life limit Local monitoring multicenter nucleic acid number Nurse Nurses objective Occurrence Older outcome participant Participants Participation Patient phase Phase III Clinical Trial Placebo placebo-controlled clinical trial pregnant pregnant women primary efficacy endpoint produced product professional professionals protocol randomisation randomised randomised controlled trial randomization randomization list randomization system Randomized receive recruitment regimen registry responsible retained Safety Sample size SARS-CoV-2 nucleic acid SARS-CoV-2 virus schedule second vaccination separation Sinovac Sinovac Life Science Sinovac Life Sciences Sponsor status stratified Study protocol subjects symptomatic case symptomatic cases symptomatic individuals systemic adverse reaction systemic adverse reactions the vaccine threshold Trial Trial registration undergo vaccination Vaccine Virological voluntary website World Health Organization [DOI] 10.1186/s13063-020-04775-4 PMC 바로가기 [Article Type] Letter
Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19혈관신생, 유전성 출혈성 모세혈관확장증 및 COVID-19Case Reports Published on 2020-10-142022-09-10 Journal: Angiogenesis [Category] 변종, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus-2 ACVRL1 Adult patients Angiogenesis characterized Clinical course Clinical data coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 patient COVID-19 pneumonia discharged disease endothelial damage endothelial injury Epistaxis Evidence Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia investigator mechanical ventilation multicenter open pathogenic pathogenic variant pathologic Patient patients Pneumonia Prevalence provoke rare disease rare diseases registry respiratory SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) telangiectasia Vascular worsening [DOI] 10.1007/s10456-020-09755-5 PMC 바로가기 [Article Type] Case Reports
Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19Case Reports Published on 2020-10-142022-10-27 Journal: Angiogenesis [Category] COVID-19, Fulltext, MERS, [키워드] ACVRL1 Angiogenesis characterized Clinical course Clinical data coronavirus disease Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 patient discharged disease endothelial damage endothelial injury Evidence Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia investigator mechanical ventilation multicenter pathogenic pathogenic variant pathologic Patient patients Pneumonia Prevalence provoke rare disease rare diseases registry respiratory SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) telangiectasia Vascular worsening [DOI] 10.1007/s10456-020-09755-5 PMC 바로가기 [Article Type] Case Reports
Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort StudyProtocol Published on 2020-10-142022-10-29 Journal: JMIR Research Protocols [Category] COVID-19, [키워드] Analysis Anosmia antimalarial arthropathy baseline benefit Brazil caused Chloroquine chronic clinical Clinical findings clinical trial collected Comorbidities Concomitant medication coronavirus cough COVID-19 COVID-19 outbreak COVID-19 patient database death demographic data diagnosed disease drug Dyspnea effective enrolled epidemiological Fever FIVE form Health Service Hospitalization Hydroxychloroquine Identifier immune system Immune-mediated immunology Impact include Inclusion individual information inhibiting intensive care knowledge lack large sample mechanisms Mortality objective Observational Observational cohort study Osteoarthritis outcome pathophysiology Patient patients treated pharmacological pharmacological management protective effect protocol recorded Region Registration registry report Research Result rheumatic disease Rheumatic diseases rheumatology SARS-CoV-2 SARS-COV-2 infection Scientific community shown the disease Treatment virus was done [DOI] 10.2196/23532 PMC 바로가기 [Article Type] Protocol
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent [DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-10-092022-10-29 Journal: Trials [Category] Coronavirus, MERS, SARS, [키워드] 1:1 All study participants allergy antiarrhythmic drug anticipated Arm assigned Bandar Abbas blinded block randomization Breastfeeding C-reactive protein clinical clinical manifestation Clinical symptoms clinical trial Clinicians company Confirmed Control Corticosteroids COVID-19 criteria Critical Department Diagnosis disease Diseases disorder dissemination diuretics dose double-blind dry cough education Effect element Eligible participants exclusion criteria feature Features Fever GI symptom GI symptoms ginger history hypertension incidence Inclusion inhibitor investigator Iran liver lung involvement lymphocytopenia Ministry of Health number Nurses objective outcome parallel group participant Patient patients pharmaceutical placebo tablet placebo-controlled clinical trial Pneumonia polymerase chain Primary outcome protocol randomization Randomized Randomized controlled trial regimen Registered registration date registry renal Research respiratory Sample size SARS-CoV-2 secondary outcome selective Serious Adverse Event serotonin reuptake inhibitor Seven single center standard treatment status Study protocol Tablet therapeutic Thyroid time tiredness treatment arm two group Version web-based system website [DOI] 10.1186/s13063-020-04765-6 PMC 바로가기 [Article Type] Letter
Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidenceResearch Article Published on 2020-10-092022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] 95% CI Abstract Adults Algorithm article case sery clinical Clinical management Co-infection conducted Controlled country COVID-19 COVID-19 group Descriptive analysis diagnostic disease duplicates eligibility eligible English Evidence Google Health HIV Human immunodeficiency virus implication IMPROVE Interaction knowledge MERS-CoV Meta-analysis Mortality observational study outcomes Pandemics Patient registry Result risk factor SARS-CoV SARS-CoV-2 screened Seven severity Severity rate spread of COVID-19 suggested systematic review TB TB patients Tuberculosis was reduced were assessed with HIV [DOI] 10.1186/s12879-020-05450-4 PMC 바로가기 [Article Type] Research Article
Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemicResearch Article Published on 2020-10-062022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] Abstract accounted addition Analysis article bioRxiv Case report Characteristics Chinese clinical clinical study clinical trial Combination COVID-19 COVID-19 pandemic cross-sectional database detect EU Clinical Trial greater International lack medRxiv mesh terms pandemic peer-reviewed prevalent proportion proportions protocols Randomized controlled trial Registered registry Regression retrieved searched significantly subject systematic review systematic reviews Trial were used [DOI] 10.1371/journal.pone.0240123 PMC 바로가기 [Article Type] Research Article
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-10-022022-10-29 Journal: Trials [Category] COVID-19, MERS, SARS, [키워드] 1:1 Ability to communicate acute respiratory syndrome addition administration age Analysis antipyretics Arm Blinding calculated clinical clinical trial Combination common cold-like symptom control group coronavirus cough COVID-19 COVID-19 patient criteria decrease defined Dementia difficulty dissemination effective Efficacy element exclusion criteria fatigue female Fever Follow-up group H1N1 influenza hospitals Hypothesis IMPROVE in both group include Inclusion Infection Inpatient Japan Japanese Kampo Kampo medicines lactating less malaise Medicine Mild-to-moderate number objective occurred outcome Outpatient parallel-group participant Patient patients positive Prevention for severe stage previous study protocol Psychiatric random Randomized Randomized controlled trial receive recruited registry required Research Sample size SARS-CoV-2 Severe infection Severity of disease Shortness of breath significance level significantly sputum Stage steroid Study protocol survival survival curve Symptom Symptom relief symptomatic temperature the Kaplan-Meier method the log-rank test the median the primary endpoint the SARS-CoV-2 to define treated Treatment Two-arm website [DOI] 10.1186/s13063-020-04746-9 PMC 바로가기 [Article Type] Letter